Eculizumab and drug-induced haemolytic–uraemic syndrome

The monoclonal anti-C5 antibody eculizumab has been successfully tested in atypical haemolytic-uraemic syndrome (aHUS), with or without mutations in the regulatory proteins of the alternative pathway of the complement, and less convincingly in enterohaemorrhagic Escherichia coli-associated HUS. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Faguer, Stanislas, Huart, Antoine, Frémeaux-Bacchi, Véronique, Ribes, David, Chauveau, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438394/
https://www.ncbi.nlm.nih.gov/pubmed/26120441
http://dx.doi.org/10.1093/ckj/sft078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438394/
https://www.ncbi.nlm.nih.gov/pubmed/26120441
http://dx.doi.org/10.1093/ckj/sft078

Ejemplares similares